Approved Medicines, Clinical Trials and “Research Use Only”: What Is the Difference?
Regulators approve specific products for specific uses; trials test investigational medicines under supervision; “research use only” labels do none of these jobs. Here is what each status actually means, and how to check it.
Three things to take away
- An approval attaches to one product, one indication, one jurisdiction — not to look-alike products, other uses or other countries.
- “Investigational” means still being studied: no regulator has decided the medicine is safe and effective for any use. The supervised route is a clinical study.
- A “research use only” label is a seller’s packaging statement, not a regulator’s clearance. Certificates document single batches, not approval or fitness for consumer use.
What “approval” actually attaches to
FDA approval covers a defined product — one named manufacturer, in specified strengths and dose forms, under defined quality standards — for listed uses called indications. The same molecule from an uncertified site, mixed by a compounding pharmacy or sold as a powder for injection is, from the regulator’s view, a different product from the one it reviewed. Approval does not belong to a molecule.
One nuance: licensed prescribers may use an approved medicine for an unapproved use (“off-label” prescribing). FDA’s patient guidance says providers may prescribe for an unapproved use when they judge it medically appropriate — though it has not determined the drug safe and effective for that use.
What “investigational” means
“Investigational” is the status of a medicine being studied in humans before any regulator has approved it. Trials test whether it helps and what harms it may cause — an open question: some never reach approval, and promising early results are not approval.
It is not freely buyable either: the routes in are trial sites with screening and consent, or regulator-authorized access for patients who cannot join a trial — not a checkout button. Approved medicines can be studied investigatively too; the label describes the open question, while approved status is a separate fact.
Retatrutide is the live example. Eli Lilly describes it as investigational; its registry records list it as such; as of 13 October 2026 no regulator has approved it, with Lilly’s first US filing said to be planned for Q1 2027. Nothing sold outside its trials is the regulated, trialed medicine.
How clinical trials are overseen
In the US, studies of unapproved medicines run under an FDA framework: an Investigational New Drug (IND) application is reviewed before human dosing, an institutional review board approves and monitors the study, participants give informed consent, and most such trials appear publicly on ClinicalTrials.gov.
South Africa runs an analogous system: SAHPRA’s clinical-trial unit reviews applications to run trials locally, authorises unregistered trial-medicine imports, and sits alongside ethics review by accredited committees; the SANCTR register publishes trials running here. Participation means enrolment, screening, consent and monitoring under an approved protocol; a parcel from an online seller carries none of that.
Why a “research use only” label is not proof of consumer safety
“Research use only” marks materials for bench research, not for treating people. On a seller’s website it is not a regulatory category making a product lawful or tested — regulators look at what a product is sold for.
The FDA has said so explicitly. In December 2025 warning letters to vendors whose products carried “research use only” and “not for human consumption” labels, the agency wrote that evidence from the labelling and websites established the products were intended to be drugs for human use — unapproved new drugs whose sale violated US law.
The peptide-specific picture agrees. On FDA’s list of bulk drug substances that may present significant safety risks in compounding, injectable GHK-Cu is flagged over immunogenicity risks from aggregation and impurities, while KPV and MOTS-c are flagged because the agency lacks human exposure data — including whether they would harm humans if administered. Peer-reviewed surveillance of semaglutide products bought online without prescriptions found concentrations far below label claims (JMIR 2024).
A research label is, in short, an instruction about a laboratory setting. No regulator assessed the product for people.
What certificates can and cannot tell you
Sellers of unregistered peptides answer doubt with paper: a certificate of analysis (CoA), sometimes a third-party lab report. A CoA can show what a laboratory measured in one batch — identity, purity, water content, contaminants. Its limits are structural:
- One batch, one test — nothing more about the vial sent to you unless chain of custody joins the two.
- Who tested it. Most CoAs come from the seller’s own supplier; documents can be copied or falsified.
- The tests chosen. Powder identity and purity are not the whole question: for injectables, sterility, endotoxins and particulates decide real-world safety — tests many certificates omit.
- Process quality. A CoA is an analytical snapshot, not evidence of manufacture under the standards required for medicines.
FDA’s compounding framework treats a “valid CoA” as one condition among several, alongside registered manufacturers and regulatory status — a certificate alone is not approval, nor assurance a product suits human use.
Different countries, different rules
Medicines regulation is national: FDA approvals cover the United States, SAHPRA registration covers South Africa — and a product approved in one country may be unregistered in another.
SAHPRA’s published position is straightforward: under the Medicines and Related Substances Act 101 of 1965, any product intended to treat, prevent or alter bodily functions must be registered with SAHPRA before it can be sold here, because registration assures safety, quality and effectiveness. Its peptide public-information page lists BPC-157, TB-500, Melanotan II, CJC-1295, Ipamorelin, PT-141, AOD-9604, Selank and Semax among peptides marketed unlawfully, warns against self-administration without medical supervision, especially for online or unverified sources, and notes risks including injection-site infection, hormonal disruption and counterfeit supply.
This article does not adjudicate the legality of buying or importing peptides in South Africa: that depends on facts — product, supplier, authorisations — and belongs to current SAHPRA sources and qualified South African legal or professional advice.
What a reader can verify today: check SAHPRA’s registered health products search; use its shelf tests (registered GLP-1 medicines are ready-to-use, prescription-only through licensed pharmacies; powder-for-injection forms are described as not registered; unusually low prices flag counterfeits); verify trials on ClinicalTrials.gov or SANCTR; and treat SAHPRA’s flagged channels — online platforms, social-media sellers, gyms, informal suppliers — with matching scepticism.
Comparison at a glance
| Aspect | Approved medicine | Investigational (trial) | “Research use only” |
|---|---|---|---|
| Purpose | Use listed by the regulator | Future use being studied | Laboratory research; not assessed for people |
| Oversight | Regulator-approved product and indications | Regulator and ethics approval, consent, monitoring | None for consumer use |
| Quality | Registered manufacturing, batch control | Trial-supplied, documented | Seller-declared; certificates cover batches |
| Access | Prescription, licensed supply chains | Enrolment at trial sites | Online sale, no gatekeeping |
| Evidence | Benefits and harms reviewed by regulator | Promise under evaluation | No regulator-reviewed human evidence |
Limitations of this article
- General information — not medical, regulatory or legal advice.
- Statuses are checked as at 13 October 2026; regulator statements change.
- No medical reviewer was involved; clinical content is limited to regulatory process.
- Jurisdiction detail covers the United States and South Africa only.
Frequently asked questions
Does approval apply to the molecule or the product?
The product — one manufacturer’s version, forms, strengths, listed indications, one jurisdiction. The same molecule can be approved in one kit and unapproved in another.
Can an approved medicine be prescribed for something else?
Yes — off-label, when a registered practitioner judges it appropriate; the regulator has not determined safety and effectiveness for that use.
If a seller shows a lab certificate, is the product safe?
It describes one batch. It does not establish approval, sterility, chain of custody, manufacturing conditions or suitability for human use.
Does a registered trial prove the product works?
No — registration records that a study is happening; a listing is not proof of benefit.
Sources
- FDA, “Understanding Unapproved Use of Approved Drugs ‘Off Label’” — https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/understanding-unapproved-use-approved-drugs-label
- FDA, “Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks” — https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- FDA warning letter, Atomix LLC, 12 December 2025 — https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/atomix-llc-719111-12122025
- FDA, Investigational New Drug (IND) Application overview — https://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-application
- ClinicalTrials.gov record NCT07629401 (retatrutide, investigational) — https://clinicaltrials.gov/study/NCT07629401
- Eli Lilly, “What to Know About Retatrutide” (manufacturer source) — https://www.lilly.com/news/stories/what-to-know-about-retatrutide
- SAHPRA, “Peptide Products – Public Information” — https://www.sahpra.org.za/peptide-products-public-information/
- SAHPRA, Clinical Trials — https://www.sahpra.org.za/clinical-trials/
- SAHPRA registered health products search — https://medapps.sahpra.org.za:6006/
- JMIR 2024;26:e65440 (semaglutide sold online without prescription) — https://www.jmir.org/2024/1/e65440
Related reading
- How to Read a Peptide Study Without Falling for the Hype — the evidence-literacy primer this article builds on.
- Retatrutide Explained — the investigational example in full context.
- Topical vs Injectable GHK-Cu — why the route changes the question.
- Peptide Research in South Africa — the local verification workflow in depth.
Want to judge peptide claims yourself? Step through our evidence guide.
If something here is wrong or outdated, tell us on our correction route — corrections are logged and dated.
